Literature DB >> 35838877

Authors' Reply to Mungmunpuntipantip et al.'s Comment on "Description of Frequencies of Reported Adverse Events Following Immunization Among Four Different COVID-19 Vaccine Brands".

Agnes Kant1, Florence van Hunsel2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35838877      PMCID: PMC9284101          DOI: 10.1007/s40264-022-01207-x

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.228


× No keyword cloud information.
Dear Editor, We read the response by Mungmunpuntipantip and Wiwanitkit [1] on our article “Description of Frequencies of Reported Adverse Events Following Immunization Among Four Different COVID-19 Vaccine Brands” [2]. Because experienced common adverse events following immunization (AEFIs) were asked for in predefined questions to all participants in the cohort we do not assume there is a high chance of underreporting. It is correct that not all mentioned events will be adverse reactions. That is incorporated in the definition of an AEFI: adverse event following immunization is any untoward medical occurrence which follows immunization and which does not necessarily have a causal relationship [3]. An experienced AEFI can also be due to nocebo effect, or background incidence. Yours sincerely Agnes Kant and Florence van Hunsel (Corresponding Author)
  1 in total

1.  Comment on "Description of Frequencies of Reported Adverse Events Following Immunization Among Four Different COVID-19 Vaccine Brands".

Authors:  Rujittika Mungmunpuntipantip; Viroj Wiwanitkit
Journal:  Drug Saf       Date:  2022-07-15       Impact factor: 5.228

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.